Group B streptococcus antigens
Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.
1. An isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:44.
2. The isolated polypeptide of claim 1 comprising the amino acid sequence set forth in SEQ ID NO: 44.
3. An isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:39.
4. The isolated polypeptide of claim 3 comprising the amino acid sequence set forth in SEQ ID NO:39.
5. An isolated polypeptide comprising (a) an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:39, and from which the N-terminal Met residue is deleted, or (b) the amino acid sequence set forth in SEQ ID NO:39, and from which the N-terminal Met residue is deleted.
6. An isolated polypeptide comprising (a) an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:39, and from which the secretory amino acid sequence is deleted, or (b) the amino acid sequence set forth in SEQ ID NO:39, and from which the secretory amino acid sequence is deleted.
7. An immunogenic composition comprising the isolated polypeptide according to either claim 1 or claim 2 and a pharmaceutically acceptable carrier or diluent.
8. An immunogenic composition comprising the isolated polypeptide according to any one of claims 3 , 4 , and 5 , and a pharmaceutically acceptable carrier, diluent or adjuvant.
9. An immunogenic composition comprising the isolated polypeptide according to claim 6 and a pharmaceutically acceptable carrier, diluent or adjuvant.
10. A method for inducing an immune response in an animal susceptible to a group B streptococcus infection, said method comprising administering to said animal the composition according to claim 7 .
11. A method for inducing an immune response in an animal susceptible to group B streptococcus infection, said method comprising administering to said animal the composition according to claim 8 .
12. A method for inducing an immune response in an animal susceptible to group B streptococcus infection, said method comprising administering to said animal the composition according to claim 9 .
13. The method according to claim 10 , wherein said animal is a bovine.
14. The method according to claim 10 , wherein said animal is a human.
15. The immunogenic composition according to claim 7 further comprising a pharmaceutically acceptable adjuvant.